Vericel

VCEL US Health Care Biotechnology
S&P 600
$38.34
+1.24%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Comfortable interest cover: operating profit covers interest about 17.5 times.
  • Net profit margin is 6%.
  • Current assets comfortably cover current liabilities (current ratio 5.03).

!Watch-points

  • Return on equity is on the lower side at 4.5%.
  • Return on capital employed is on the lower side at 2.4%.

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreSafe zone
8.95

In Altman’s original study, companies in this range showed a low incidence of financial distress.

Piotroski F-ScoreStrong
7 / 7

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 7 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap$1.96B
Current Price$ 38.34
High / Low$ 49.32 / 28.95
Stock P/E79.875
Book Value$ 7.07
Dividend Yield0%
ROCE2.43%
ROE4.46%
Current Ratio5.03
P/B Ratio5.302171
EPS$ 0.32
PAT Margin5.98%
Cash PAT$28.06M
ICR17.53
Educational data only. Not a recommendation to buy, sell or hold any security.